Drug trial shows promising results to fight Huntington's disease

For the first time, an experimental drug has reduced levels of the toxic protein that causes Huntington's disease in ...

Posted: Dec 11, 2017 6:20 PM
Updated: Dec 11, 2017 6:20 PM

For the first time, an experimental drug has reduced levels of the toxic protein that causes Huntington's disease in humans.

Huntington's disease is an inherited disorder in which mutant forms of the huntingtin protein damage nerve cells in the brain.

Ionis-HTTRx is the first drug to reduce levels of the toxic protein behind Huntington's

It's hoped this form of drug could be adapted to target proteins in other brain disorders

The new drug, Ionis-HTTRx, was shown to be safe in humans and lowered levels of mutant huntingtin protein in the nervous systems of trial participants.

"The results of this trial are of groundbreaking importance for Huntington's disease patients and families," said Sarah Tabrizi, director of University College London's Huntington's Disease Centre, who led the trial. "The key now is to move quickly to a larger trial to test whether the drug slows disease progression."

The trial involved 46 patients at early stages of the disease who were enrolled across nine centers in the UK, Germany and Canada. Initial results were announced Monday.

Each patient received four doses of either the new drug or a placebo, injected directly into spinal fluid so it could easily reach the brain. For those receiving the drug, the dose was increased over time, and safety was monitored throughout, according to a statement.

Concentrations of the toxic protein were measured in the patients' spinal fluid before and after the injections.

Among people receiving Ionis-HTTRx, the team saw a significant decline in levels of mutant huntingtin, which causes symptoms of the disease, with higher doses having greater impact. This is the first time the protein has been lowered in patients with the condition.

"The results are encouraging, as it shows delivering therapeutic agents of this type is feasible and well-tolerated and the treatment has done what it said it would: namely, drop the relevant protein levels," said Roger Barker, professor of clinical neuroscience and honorary consultant neurologist at the University of Cambridge, who worked with six patients involved in the trial.

"The question is whether this is enough to make a difference to patients and their clinical course, and that we will have to wait for bigger trials," he said.

The team now plans to conduct a larger-scale trial in hundreds of patients across multiple centers, said Ed Wild, a principal researcher at UCL's Huntington's Disease Centre, who worked on the trial with Tabrizi.

Hunting down huntingtin

Huntington's disease is an inherited neurodegenerative disorder in which nerve cells in the brain are damaged, causing uncontrolled movements, changes in behavior and emotions, and altered cognition.

The disease typically begins affecting people between the ages of 30 and 50 and gets progressively worse over time. Children of a parent with the disease have a 50% chance of inheriting the mutant gene.

An estimated 30,000 Americans are living with the disease. About 10,000 people in the UK have it, and a further 25,000 are at risk.

The condition is caused by a mutation in the huntingtin gene, which encodes the huntingtin protein, which is needed for normal development before birth and thought to help brain cells function, though the exact function is unknown. The mutant form of this protein accumulates and binds together to become toxic to certain brain cells, eventually killing them.

A drug with the ability to reduce levels of the toxic protein would mean progression of the disease could be slowed or even stopped.

"The details of this study have not been peer-reviewed or published yet, so the scientific community simply does not know yet how robust the findings are," noted Tara Spires-Jones, deputy director of the Centre for Discovery Brain Sciences at the University of Edinburgh, who was not involved in the research.

"With that caveat in mind, the approach used in this trial has excellent potential to prevent Huntington's disease," she said, "and if the next stage of larger trials live up to their promise, this will be a breakthrough."

How the drug works

The drug consists of a single strand of DNA that targets genetic material within brain cells, called mRNA, that helps translate genes into proteins.

In this case, the drug specifically sought out mRNA that helps translate huntingtin genes into huntingtin proteins and stopped production of the protein -- both the healthy and toxic forms.

"Less of the protein is made," Wild said, adding that the healthy form of the protein is known to play a vital role in early childhood development but not necessarily during adulthood, whereas the toxic form damages nerve cells in adults. "That protein is the cause of all of the problems" in Huntington's disease.

'A game-changer'?

It's hoped this form of drug could be adapted to target proteins in other currently incurable brain disorders, such as Alzheimer's disease.

By changing the DNA sequence in the drug, researchers can target any mRNA, Wild said. In other neurodegenerative diseases, "there is at least one protein you would like to partially reduce," he said. One example is tau protein in Alzheimer's disease. "This is proof of principle you can inject these drugs into spinal fluid; they get into the brain and reduce harmful proteins."

"This is a potential game-changer, not only for Huntington's disease patients but also for genomic medicine in general," said Philippa Brice of health policy think tank the PHG Foundation.

"Though more work needs to be done, if gene silencing lives up to this promise, we could be on the brink of some of the personalized treatments that patients with severe genetic diseases need so badly. But this will also raise further questions for society and for policy-makers about how best to use such a powerful technique," Brice said.

The drug was developed by Ionis Pharmaceuticals but has been taken over by Roche, which will lead the development of the next, larger trial and handle future licensing of the drug, Wild said. The full results of the trial and plans for future trials will be presented next year.

Huntsville
Broken Clouds
77° wxIcon
Hi: 79° Lo: 54°
Feels Like: 78°
Florence
Clear
78° wxIcon
Hi: 79° Lo: 56°
Feels Like: 79°
Fayetteville
Broken Clouds
75° wxIcon
Hi: 78° Lo: 51°
Feels Like: 75°
Decatur
Broken Clouds
77° wxIcon
Hi: 78° Lo: 52°
Feels Like: 78°
Scottsboro
Scattered Clouds
77° wxIcon
Hi: 78° Lo: 53°
Feels Like: 79°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

Alabama Coronavirus Cases

Confirmed Cases: 128818

Reported Deaths: 2284
CountyConfirmedDeaths
Jefferson18911337
Mobile13039289
Montgomery8628173
Madison750775
Tuscaloosa7180114
Lee570559
Shelby564550
Baldwin504749
Marshall382143
Etowah333447
Calhoun332039
Morgan318126
Houston269922
Elmore251947
DeKalb234619
St. Clair221335
Walker220780
Talladega205026
Limestone197319
Cullman183017
Franklin174128
Dallas173626
Russell17112
Autauga167324
Lauderdale164133
Colbert159326
Escambia155725
Blount154214
Jackson149411
Chilton147127
Dale132743
Covington130227
Coffee12708
Pike11519
Tallapoosa113183
Chambers112342
Clarke104917
Marion93728
Butler90838
Barbour8307
Marengo69919
Winston69912
Lowndes64527
Pickens63114
Bibb62810
Hale61228
Randolph60712
Bullock58514
Lawrence58220
Monroe5758
Geneva5634
Cherokee55516
Washington54413
Perry5376
Clay5367
Wilcox53011
Conecuh52311
Crenshaw52231
Macon47620
Henry4674
Fayette4189
Sumter41819
Lamar3452
Choctaw34412
Cleburne3206
Greene30015
Coosa1613
Out of AL00
Unassigned00

Tennessee Coronavirus Cases

Confirmed Cases: 181439

Reported Deaths: 2216
CountyConfirmedDeaths
Shelby29800446
Davidson25840289
Hamilton903388
Rutherford890287
Knox880672
Williamson503036
Sumner462993
Wilson331841
Putnam301937
Montgomery292243
Bradley281816
Out of TN281123
Unassigned28036
Madison259656
Sevier250013
Blount242523
Maury218323
Robertson215133
Washington212332
Sullivan203831
Hamblen183125
Tipton171117
Trousdale16477
Hardeman151325
Gibson149219
Wayne14785
Bedford129516
Dyer125312
Dickson117612
Cumberland114317
Anderson111711
Fayette111118
Carter110827
Weakley110419
Henderson110119
Loudon10996
Greene107936
Coffee106912
Obion10669
Jefferson105114
McMinn104524
Macon100719
Warren9977
Monroe99416
Hardin95414
Lawrence93911
Lauderdale92815
Haywood90016
Franklin8757
Lake8712
Bledsoe8444
Roane8284
Carroll81617
Cheatham78410
McNairy78316
Rhea76611
White7639
Hawkins74716
Cocke7309
Marshall6985
Overton6734
Smith66910
Johnson6352
Henry5949
Chester5769
Lincoln5761
Giles54917
DeKalb54111
Hickman5154
Crockett49719
Marion4937
Decatur4556
Claiborne4234
Fentress4223
Campbell4153
Polk37511
Grainger3462
Benton3319
Union3311
Jackson3024
Morgan3023
Unicoi2741
Cannon2690
Grundy2305
Humphreys2243
Sequatchie2193
Meigs2163
Scott1972
Clay1825
Houston1780
Lewis1691
Stewart1672
Van Buren1490
Moore1451
Perry1400
Hancock1063
Pickett942

Community Events